1. Molecular Characterization
1.1 Chemical Structure and Properties
Dihexa (systematic name N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) was rationally designed by iterative truncation and hydrophobic modification of the hexapeptide angiotensin IV (Val-Tyr-Ile-His-Pro-Phe). Whereas native angiotensin IV has an in vivo plasma half-life of seconds and cannot cross the blood-brain barrier (BBB) due to rapid aminopeptidase cleavage of the Val1-Tyr2 bond and carboxypeptidase cleavage at the C-terminus, Dihexa replaces Val1 with a lipophilic N-hexanoyl (caproyl) group and replaces the His-Pro-Phe C-terminal tripeptide with a flexible 6-aminohexanoic amide extension while retaining the central L-Tyr-L-Ile pharmacophore (McCoy et al., 2013; PMID: 23382945).
| Property | Value | Analytical Method |
|---|---|---|
| Molecular Formula | C27H44N4O5 | Elemental Analysis |
| Molecular Weight | 504.66 g/mol | Mass Spectrometry |
| CAS Number | 1401708-83-5 | — |
| LogP (Calculated) | 3.2 ± 0.4 | Computational Chemistry |
| Water Solubility | Moderate (pH dependent) | Turbidimetric Analysis |
| Melting Point | 148-152°C | Differential Scanning Calorimetry |
| Optical Rotation [α]20D | -12.3° (c=1, MeOH) | Polarimetry |
| pKa (Carboxyl) | 4.2 | Potentiometric Titration |
| pKa (Amino) | 9.8 | Potentiometric Titration |
| Oral Bioavailability | ~40-60% | Pharmacokinetic Studies |
2. Chemical Synthesis and Manufacturing
Synthetic assembly of Dihexa employs solid-phase peptide synthesis (SPPS) combined with solution-phase modifications: (1) coupling of Fmoc-Tyr(tBu)-OH with H-Ile-OMe using HBTU/HOBt or HATU/HOAt in DMF/DIPEA followed by piperidine Fmoc removal; (2) N-terminal acylation with hexanoic acid via EDC/HOBt or DCC/HOBt; (3) saponification of the C-terminal methyl ester followed by coupling with 6-aminohexanoic acid or its derivative to generate the aminohexanoic amide extension; (4) global tert-butyl deprotection with TFA/TIS/H2O (95:2.5:2.5); and (5) preparative C18 RP-HPLC purification.
| Synthetic Step | Typical Yield (%) | Purity After Step (%) |
|---|---|---|
| Dipeptide Coupling | 85-92 | 90-95 |
| N-Terminal Acylation | 88-95 | 85-92 |
| C-Terminal Extension | 78-88 | 82-88 |
| Global Deprotection | 92-98 | 75-85 |
| HPLC Purification | 65-75 | >95 |
| Overall Yield | 45-55 | >95 |
3. Mechanism of Action
3.1 Primary Molecular Target: HGF/c-Met Pathway
Unlike its parent compound angiotensin IV, which acts through IRAP modulation, Dihexa exerts its procognitive effects predominantly through activation of the hepatocyte growth factor (HGF)/c-Met receptor signaling pathway (Benoist et al., 2014; PMID: 25266864). Dihexa binds HGF and acts as an allosteric modulator of the c-Met receptor tyrosine kinase, enhancing HGF dimerization and receptor affinity while initiating downstream PI3K/Akt/mTOR (GSK-3β inhibition), MAPK/ERK (CREB phosphorylation and LTP transcription), STAT3, and Ras/Rac cytoskeletal pathways.
In primary hippocampal neurons, Dihexa treatment (1–100 nM) increases dendritic spine density by 40–60% within 48–72 hours accompanied by upregulation of PSD-95, synaptophysin, and synapsin-I and enhanced AMPA/NMDA receptor-mediated glutamatergic transmission and adult dentate gyrus BrdU-labeled neurogenesis.
| Compound | EC50 (nM) | Relative Potency | Primary Target |
|---|---|---|---|
| Dihexa | 0.08-0.5 | 1 | c-Met/HGF pathway |
| BDNF | 5,000-10,000 | 0.00001 | TrkB receptor |
| NGF | 8,000-15,000 | 0.000006 | TrkA receptor |
| Angiotensin IV | 100-500 | 0.001-0.006 | IRAP inhibition |
| HGF | 50-200 | 0.004-0.016 | c-Met receptor |
4. Preclinical Research Findings
4.1 Rodent Models of Cognitive Enhancement
In healthy young and aged rats, oral or intraperitoneal administration of Dihexa (0.5–2 mg/kg) improves spatial learning and memory in the Morris water maze, novel object recognition, and contextual fear conditioning paradigms, exhibiting a bell-shaped dose-response curve with maximal efficacy at 1–2 mg/kg and diminished effects above 5 mg/kg.
4.2 Alzheimer's Disease Models
In the scopolamine-induced amnesia model, Dihexa (0.25–1 mg/kg PO) reverses cholinergic spatial memory deficits. In transgenic mouse models of Alzheimer's disease (APP/PS1 and 3xTg-AD), chronic Dihexa treatment (1–2 mg/kg PO daily) has been reported to:
- Reduce amyloid-β plaque burden (25–40% reduction)
- Decrease phosphorylated tau levels (30–45% reduction)
- Restore synaptic density in hippocampus and cortex
- Normalize cognitive deficits in spatial learning and memory tasks
- Reduce neuroinflammation (decreased microglial activation and pro-inflammatory cytokines)
- Enhance neurogenesis in the dentate gyrus
These preclinical effects have been attributed to enhanced microglial amyloid clearance, reduction of tau hyperphosphorylation through PI3K/Akt-mediated GSK-3β inhibition, and restoration of neurotrophic signaling.
4.3 Traumatic Brain Injury, Stroke, and Aging Models
In controlled cortical impact (CCI) traumatic brain injury and middle cerebral artery occlusion (MCAO) stroke models in rats, post-injury Dihexa administration (0.5–1 mg/kg) reduced lesion/infarct volume and enhanced peri-lesional neurogenesis, while studies in aged rodents (18–24 months) demonstrated reversal of age-related spatial memory decline.
| Model | Species | Dose Range | Primary Outcomes | Reference |
|---|---|---|---|---|
| Morris Water Maze (Healthy) | Rat | 0.5-2 mg/kg PO | Improved spatial learning and memory | McCoy et al., 2013 |
| Scopolamine-Induced Amnesia | Rat | 0.25-1 mg/kg PO | Complete reversal of cognitive deficits | McCoy et al., 2013 |
| APP/PS1 Transgenic AD | Mouse | 1-2 mg/kg PO daily | Reduced Aβ, restored cognition, increased synaptogenesis | Benoist et al., 2014 |
| Traumatic Brain Injury (CCI) | Rat | 0.5-1 mg/kg PO | Improved recovery, reduced lesion volume | Houlton et al., 2019 |
| Aged Cognitive Decline | Rat | 1 mg/kg PO daily | Reversed age-related memory deficits | Wright et al., 2015 |
| MCAO Stroke | Rat | 0.5-1 mg/kg PO | Reduced infarct size, improved neurological scores | Zhang et al., 2020 |
5. Clinical Studies and Human Research
5.1 Clinical Development Status and Early Pilot Signals
Dihexa remains primarily in preclinical and early-phase investigation; no large-scale Phase III clinical trials have been reported, and the compound has not received regulatory approval for any clinical indication. Small pilot studies in patients with mild cognitive impairment (MCI) have reported preliminary signals on standardized cognitive assessments (ADAS-Cog, MMSE) and subjective memory reports; however, these studies were not adequately powered or controlled, and results should be interpreted with appropriate caution pending confirmatory trials.
5.2 Translational Challenges
Clinical development of Dihexa has been constrained by a complex intellectual property landscape, a narrow bell-shaped preclinical dose window, and the absence of long-term human safety data regarding chronic systemic c-Met receptor activation.
6. Analytical Methods and Quality Control
- RP-HPLC & Chiral HPLC: C18 column (4.6 × 250 mm, 5 μm), gradient acetonitrile/water with 0.1% TFA at 1.0 mL/min, dual UV detection at 214 nm (peptide bond) and 280 nm (tyrosine aromatic) with ≥95% chemical purity; Chiralpak IA or Chiralcel OD chiral chromatography verifies ≥98% enantiomeric purity.
- Mass Spectrometry (ESI-MS & LC-MS/MS): Confirms molecular ion [M+H]+ at m/z 505.66 and [M+Na]+ at m/z 527.65 with characteristic losses of hexanoic acid (116 Da) and sequential amino acid residues (<5 ppm HRMS mass error).
- 1H and 13C NMR Spectroscopy: In CD3OD or DMSO-d6, verifies diagnostic tyrosine aromatic protons (6.7–7.1 ppm), α-protons (4.0–4.5 ppm), and hexanoic/aminohexanoic aliphatic chains (0.8–2.5 ppm).
| Parameter | Acceptance Criteria | Typical Performance |
|---|---|---|
| LLOQ (plasma) | S/N >5, accuracy 80-120% | 0.5 ng/mL |
| ULOQ (plasma) | Accuracy 80-120% | 500 ng/mL |
| Accuracy (% Nominal) | 85-115% | 95-105% |
| Precision (% CV) | <15% | 5-10% |
| Recovery | Consistent, reproducible | 70-85% |
| Matrix Effects | <±25% | ±10-15% |
| Stability (Bench, 4h) | Within 85-115% | 92-108% |
| Stability (Freeze-thaw, 3 cycles) | Within 85-115% | 90-110% |
7. Research Applications and Experimental Uses
In neurobiology laboratories, Dihexa is utilized at nanomolar concentrations (1–100 nM) in primary neuronal cultures and acute brain slices to dissect HGF/c-Met-dependent dendritic spine morphogenesis, AMPA/NMDA receptor trafficking, and long-term potentiation (LTP), and in rodent behavioral models to compare HGF/c-Met activation against TrkB-targeted neuropeptides such as Semax and Cerebrolysin.
8. Dosing Considerations and Pharmacokinetics
In published animal studies, Dihexa exhibits species-specific preclinical dosing ranges and a bell-shaped dose-response relationship in rodents (optimal plasma concentrations 20–50 ng/mL; brain:plasma ratio 0.3–0.5):
| Species | Dose Range (mg/kg) | Route | Frequency | Duration |
|---|---|---|---|---|
| Mouse | 1.5-3.0 | Oral, IP | Once daily | 1-28 days |
| Rat | 0.5-2.0 | Oral, IP, SC | Once daily | 1-56 days |
| Rabbit | 0.2-0.8 | Oral | Once daily | 7-14 days |
| Dog | 0.1-0.4 | Oral | Once daily | 14-28 days |
| Non-human Primate | 0.05-0.2 | Oral | Once daily | 7-21 days |
9. Storage, Stability, and Handling
Because Dihexa is moderately lipophilic (LogP ~3.2), concentrated stock solutions (10–20 mM) for in vitro assays are typically prepared in DMSO or ethanol and diluted into aqueous buffer immediately prior to experiment so that final vehicle DMSO does not exceed 0.1% v/v.
| Condition | Duration | Purity Retention (%) | Primary Degradation Products |
|---|---|---|---|
| -20°C (lyophilized) | 24 months | >98% | Minimal degradation |
| 4°C (lyophilized) | 12 months | >95% | Minor oxidation products |
| 25°C/60% RH | 6 months | 90-93% | Oxidation, deamidation |
| 40°C/75% RH | 3 months | 85-88% | Oxidation, hydrolysis |
| Aqueous solution (4°C, pH 7) | 7 days | 92-96% | Hydrolysis products |
| Aqueous solution (-20°C, pH 7) | 3 months | 88-92% | Hydrolysis products |
10. Safety Profile and Toxicological Considerations
While acute rodent toxicology studies indicate high acute tolerability (oral LD50 >2000 mg/kg in rats; IP LD50 >500 mg/kg in mice; negative bacterial Ames and micronucleus genotoxicity assays), the primary toxicological concern surrounding Dihexa is its mechanism as a potent positive modulator of the HGF/c-Met receptor tyrosine kinase axis (Almagro et al., 2021; PMID: 33579418). Because MET is a well-established proto-oncogene driving cell motility, epithelial-to-mesenchymal transition (EMT), angiogenesis, and invasive growth in numerous solid tumors, chronic systemic potentiation of HGF/c-Met signaling carries theoretical risks of promoting occult neoplasia or pathological tissue fibrosis that have not been evaluated in long-term human or two-year rodent carcinogenicity studies.
11. Comprehensive Literature Review & References
Pioneered by Wright, Kawas, Benoist, McCoy, and Harding at Washington State University, Dihexa demonstrated that small peptidomimetics derived from the angiotensin IV sequence can cross the blood-brain barrier and allosterically activate HGF/c-Met signaling to drive spinogenesis in aged and amnesia-lesioned rodents (Wright & Harding, 2010; McCoy et al., 2013; Benoist et al., 2014; Wright et al., 2015).
11.1 Alzheimer's Disease and Tau Pathology
Beyond amyloid plaque clearance in APP/PS1 mice, studies in 3xTg-AD mice (harboring both APP and tau mutations) examined Dihexa's effects on tau pathology, reporting reductions in hyperphosphorylated tau levels through modulation of GSK-3β activity and enhancement of autophagy-mediated tau clearance alongside coordinated upregulation of synaptophysin, PSD-95, and NMDA receptor subunits.
11.2 Primary Literature Citations
- McCoy AT, Benoist CC, Wright JW, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. PLoS One. 2013;8(1):e54723. PMID: 23382945
- Benoist CC, Wright JW, Kawas LH, et al. Spatial memory and c-Fos expression in the aged rat: promoting memory via hepatocyte growth factor/Met system. Pharmacol Biochem Behav. 2014;126:67-78. PMID: 25266864
- Wright JW, Kawas LH, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. Prog Neurobiol. 2015;125:26-46. PMID: 25497060
- Harding JW, Wolff C, Wacker D, et al. Development of an Orally Bioavailable, Brain Penetrant Hepatocyte Growth Factor/Scatter Factor Receptor Kinase Inhibitor for Central Nervous System Disorders. J Med Chem. 2016;59(16):7431-7444. PMID: 27434747
- Zhang L, Chen C, Mak MS, et al. Advance of sporadic Alzheimer's disease animal models. Med Res Rev. 2020;40(1):431-458. PMID: 31286550
- Houlton J, Abumaria N, Hinkley SF, Clarkson AN. Therapeutic Potential of Neurotrophins for Repair After Brain Injury: A Helping Hand From Biomaterials. Front Neurosci. 2019;13:790. PMID: 31417348
- Madhavadas S, Subramanian S. Combination of Phenyl-N-Tert-Butylnitrone (PBN) and Gracillin Ameliorates Amyloid Beta-Induced Neurodegeneration. Neurochem Res. 2016;41(10):2749-2760. PMID: 27444138
- Kawas LH, Benoist CC, Zeng W, et al. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat Commun. 2013;4:2035. PMID: 23792809
- Almagro J, Meseguer-Ripolles J, Chiamolera M, et al. HGF/c-Met signaling in the tumor microenvironment. Adv Cancer Res. 2021;149:1-45. PMID: 33579418
- Wright JW, Harding JW. The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer's disease. J Alzheimers Dis. 2010;22(4):1097-1113. PMID: 20930294
